Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SGN-MesoC2 |
Synonyms | |
Therapy Description |
SGN-MesoC2 is an antibody-drug conjugate (ADC) comprising an anti-MSLN antibody linked to a camptothecin-based topoisomerase I inhibitor, which potentially induces cytotoxicity in MSLN-expressing tumor cells and antitumor activity (Cancer Res (2025) 85 (8_Supplement_1): 324). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SGN-MesoC2 | SGN MesoC2|SGNMesoC2|PF08052666|PF 08052666|PF08052666|HBM9033 | MSLN Antibody 13 | SGN-MesoC2 is an antibody-drug conjugate (ADC) comprising an anti-MSLN antibody linked to a camptothecin-based topoisomerase I inhibitor, which potentially induces cytotoxicity in MSLN-expressing tumor cells and antitumor activity (Cancer Res (2025) 85 (8_Supplement_1): 324). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06466187 | Phase I | SGN-MesoC2 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Recruiting | USA | CAN | 0 |